echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Bristol-Myers Squibb BCMA CAR-T therapy Abecma receives EU CHMP support

    Bristol-Myers Squibb BCMA CAR-T therapy Abecma receives EU CHMP support

    • Last Update: 2021-09-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Compileriver

    A few days ago, according to foreign media reports, Bristol-Myers Squibb (BMS) announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended to grant Abecma (idecabtagene vicleucel, ide-cel) conditional marketing authorization


    CHMP adopted positive opinions based on the results of the pivotal Phase II KarMMa study, which evaluated the efficacy and safety of Abecma in 128 patients with severe pre-treatment and highly refractory multiple myeloma


    The results showed that in the efficacy evaluation population (n=100), the overall response rate (ORR) of Abecma single infusion therapy was 72% (95%CI: 62-81), and 28% of patients achieved strict complete remission ( sCR; 95%CI: 19-38)


    In this study, the safety of Abecma in treated patients has been well confirmed.


    It is worth mentioning that Abecma is the world's first BCMA-directed CAR-T cell therapy to receive regulatory approval.


    EC expects to make a final decision within 67 days after receiving the CHMP opinion


    Reference source:

    1.


    2.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.